Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic alpha-MSH analogue and predominant MC1R agonist
MT-1 is a common name for afamelanotide. The FDA-approved version is SCENESSE, a clinician-placed implant used for one rare condition— erythropoietic protoporphyria—to help adults tolerate more light without pain. Research also describes pigmentation, vitiligo combination therapy, and EPP-related liver questions, but those are not the same as an approved cosmetic tanning product or a general-use injectable peptide.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
MT-1 is a common name for afamelanotide. The regulated version, SCENESSE, is a clinician-placed implant for adults with a rare light-sensitivity disorder called erythropoietic protoporphyria.
Afamelanotide increases darker skin pigment through a melanocortin signal, which may let people with that disorder tolerate more light without pain. Researchers have also explored vitiligo and other condition-specific questions.
Two controlled trials found more pain-free light exposure in adults with erythropoietic protoporphyria using the specific implant. A small vitiligo study combined implants with ultraviolet-B therapy, so it cannot establish afamelanotide alone.
Rare long-term harms, pediatric use, pigment surveillance, liver outcomes, and other skin indications remain incomplete. The approved implant is not a cosmetic tanning product and does not validate injectable or reconstituted MT-1.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Two pivotal controlled trials evaluated the regulated afamelanotide implant in adults with erythropoietic protoporphyria.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Afamelanotide has controlled pivotal trials, an approved product, pharmacokinetic data, postauthorization cohorts, and investigational dermatology research.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Controlled trials and current labeling support increased pain-free light exposure in adults with EPP; confidence does not extend to cosmetic tanning or unapproved formulations.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The trials used a specific controlled-release implant in a rare-disease population. The findings do not establish cosmetic tanning, ultraviolet protection, self-injection, or equivalence to reconstituted material. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Two randomized, double-blind, placebo-controlled EPP trials involving 168 adults, supported by the current FDA label and postauthorization cohorts of 117 and 200 patients.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
How long-term rare safety, pigmentary surveillance, pediatric use, off-label skin indications, liver outcomes, and non-implant formulations compare with the well-defined SCENESSE evidence record.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Afamelanotide is also called NDP-alpha-MSH and Melanotan I. SCENESSE contains 16 mg of afamelanotide in a sterile bioresorbable controlled-release implant.
MC1R signaling in melanocytes increases darker eumelanin pigment. This explains the pigmentation effect and contributes to the EPP treatment rationale.
The approval is tied to the named 16 mg implant, adult EPP population, professional implantation, and product label.
Both pivotal trials favored afamelanotide for pain-free sunlight exposure; the European trial also recorded fewer phototoxic reactions.
A 117-person practice cohort reported more time outside, and a 200-person German registry reported better quality of life and high treatment continuity.
The combination outperformed UV-B alone in 55 adults, especially among the darker skin phototypes studied.
The label documents generalized pigmentation, skin hyperpigmentation, and darkening of existing nevi and freckles while still requiring sun and light protection.
In controlled EPP trials, implant-site reactions occurred in 21% with SCENESSE versus 10% with vehicle and nausea in 19% versus 14%. Postmarketing anaphylaxis has been reported.
The implant is placed subcutaneously by a trained healthcare professional under an aseptic procedure every two months for the approved EPP use.
A 70-person retrospective study associated implant exposure with lower protoporphyrin and selected liver-test values.
Average vitamin-D levels did not significantly increase with afamelanotide alone, even though the treatment can increase pain-free light exposure.
The sealed implant is refrigerated at 2°C to 8°C and protected from light. It is a finished bioresorbable product and requires no reconstitution.
Mechanisms
Afamelanotide is a synthetic tridecapeptide analogue of alpha-melanocyte-stimulating hormone that binds predominantly to MC1R and increases cutaneous eumelanin independently of UV exposure. Two randomized EPP trials demonstrated longer pain-free sunlight exposure and improved quality of life with a 16 mg controlled-release implant. Postauthorization cohorts support real-world effectiveness but lack concurrent untreated controls. A small randomized study found faster vitiligo repigmentation only when the implant was combined with narrowband UV-B. Liver and vitamin-D findings remain observational. The current label adds a serious-hypersensitivity boundary and recommends twice-yearly skin monitoring.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Two multicenter, randomized, double-blind, placebo-controlled trials
Adults with erythropoietic protoporphyria
Pain-free sunlight exposure was longer with afamelanotide in both trials. The European trial also recorded fewer phototoxic reactions, and quality-of-life measures improved in both studies.
Study administration: A 16 mg controlled-release subcutaneous afamelanotide implant or placebo every 60 days under the trial protocols
Limitations: The two trials used different sunlight windows and follow-up periods, relied on patient-recorded exposure, and studied a rare EPP population using a specific controlled-release implant. Results do not transfer to cosmetic tanning or unapproved formulations.
Randomized multicenter trial of combination therapy versus narrowband UV-B phototherapy alone
Adults with stable or slowly progressive nonsegmental vitiligo affecting 15% to 50% of body surface area and Fitzpatrick skin types III to VI
The combination produced faster and greater average repigmentation than UV-B alone, with the clearest signal in darker studied skin phototypes.
Study administration: Narrowband UV-B alone or narrowband UV-B plus four monthly 16 mg afamelanotide implants after a one-month phototherapy lead-in
Limitations: This was a small off-label combination study. It cannot isolate afamelanotide from UV-B, does not establish afamelanotide monotherapy, and did not support an FDA-approved vitiligo indication.
Ongoing German observational registry and postauthorization safety study
German patients with EPP receiving afamelanotide
Quality-of-life scores increased from baseline and 91% of participants who began treatment were still receiving it at the analysis cutoff. The reported safety pattern was consistent with the clinical-trial profile.
Study administration: SCENESSE 16 mg implant according to the European product information
Limitations: Every analyzed participant was treated, so there was no untreated comparator. The study and registry received Clinuvel support, and several authors reported company employment, stock, or research support.
Longitudinal multicenter cohort comparing routine vitamin-D measurements across treatment-exposure groups
Adults with EPP in the Netherlands and Germany
Afamelanotide alone was not associated with a significant average vitamin-D increase. Cholecalciferol-containing groups had higher levels.
Study administration: Observed exposure to no treatment, cholecalciferol, afamelanotide, or both
Limitations: This was observational and not randomized. It addresses vitamin-D laboratory values in EPP, not broader health outcomes or an individualized supplement plan.
Retrospective repeated-measures observational study of laboratory records and implant exposure
Patients with EPP receiving clinical afamelanotide implants
More recent and more frequent implant exposure was associated with lower protoporphyrin and selected liver-test values in the statistical models.
Study administration: Clinical afamelanotide implant exposure over time
Limitations: Retrospective association does not prove liver protection. Patient-level differences, season, indication, treatment selection, repeated testing, and reported company relationships may influence the findings.
Single-center prospective postauthorization safety and effectiveness cohort
Patients with EPP treated in routine clinical practice
During treatment, participants reported about 6.1 more hours outside per week and improved EPP-specific quality of life. Phototoxic reactions were reported as less painful, while their number and duration did not significantly change.
Study administration: Afamelanotide implant in clinical practice
Limitations: This observational cohort had no untreated concurrent comparator, used self-reported outcomes, and cannot separate treatment effects from season, behavior, expectations, or selection into care.
Safety snapshot
Important known safety findings include implant-site reactions, nausea, pigment changes, and rare serious hypersensitivity reactions.
Controlled human evidenceTrial rates do not capture every rare or long-term event. The current label contraindicates SCENESSE after severe hypersensitivity and recommends twice-yearly full-body skin examinations.
Open sourceImportant known safety findings include implant-site reactions, nausea, pigment changes, and rare serious hypersensitivity reactions.
Controlled human evidenceLow-frequency estimates are sensitive to sample size, follow-up, ascertainment, formulation, and population.
Open sourceNo source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryFDA approved only as the SCENESSE 16 mg bioresorbable subcutaneous implant to increase pain-free light exposure in adults with EPP. Other products, formulations, populations, and uses are not covered by that approval. How long-term rare safety, pigmentary surveillance, pediatric use, off-label skin indications, liver outcomes, and non-implant formulations compare with the well-defined SCENESSE evidence record.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
In controlled EPP trials, implant-site reactions occurred in 21% with SCENESSE versus 10% with vehicle and nausea in 19% versus 14%. Postmarketing anaphylaxis has been reported.
Controlled human evidenceUrgent-action language is product- and context-specific. Consult the linked current label or source rather than generalizing it to other formulations.
Open sourceCommunity
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-05-11 · NCT01605136; NCT00979745
2025-03-01 · PMID 40082741 · EUPAS13004 · DOI 10.1111/phpp.13012
2024-04-18 · PMID 38634774 · DOI 10.1093/bjd/ljae148
2023-04-21 · PMID 37109595 · DOI 10.3390/life13041066
2020-03-18 · PMID 32186677 · DOI 10.1001/jamadermatol.2020.0352
2015-07-02 · PMID 26132941 · NCT01605136; NCT00979745 · DOI 10.1056/NEJMoa1411481
2014-09-17 · PMID 25230094 · NCT01430195 · DOI 10.1001/jamadermatol.2014.1875